Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic Melanoma

NCT06204991 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT06204991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06204991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic Melanoma
Lead sponsor
Inge Marie Svane
Phase
Phase 1
Overall status
Recruiting
Start date
April 1, 2025
Completion date
April 1, 2028
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma stage iii, melanoma stage iv